{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:20:43Z","timestamp":1789701643262,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtha.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:09:13Z","timestamp":1760062153000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Garidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Crichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-4732","authenticated-orcid":false,"given":"Corinne","family":"Frere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.09.009_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2025.7529","article-title":"Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines","volume":"334","author":"Metcalf","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.009_bib4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.009_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2014.118075","article-title":"Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis","volume":"100","author":"Stanworth","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.09.009_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3324\/haematol.2020.250720","article-title":"The never ending success story of tranexamic acid in acquired bleeding","volume":"105","author":"Franchini","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.09.009_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12546","article-title":"Tranexamic acid evidence and controversies: an illustrated review","volume":"5","author":"Relke","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.009_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ejh.13348","article-title":"The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients","volume":"104","author":"Cai","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/ejh.13555","article-title":"Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: a Dutch nationwide survey","volume":"106","author":"Cornelissen","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","article-title":"Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia","volume":"2","author":"Avvisati","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199509059668","article-title":"A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia","volume":"19","author":"Shpilberg","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.009_bib14","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(24)00317-X","article-title":"Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial","volume":"12","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.09.009_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtha.2025.09.009_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jtha.2025.09.009_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtha.2025.09.009_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jtha.2025.09.009_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2025.09.009_bib20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/bloodadvances.2022008255","article-title":"Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia","volume":"7","author":"Ilich","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.09.009_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0036-1597283","article-title":"Platelet-mediated modulation of fibrinolysis","volume":"43","author":"Whyte","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.09.009_bib22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood.V108.11.1503.1503","article-title":"Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 protocols","volume":"108","author":"Montesinos","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.009_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013483","article-title":"Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study","volume":"6","author":"Tay","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/biom.13238","article-title":"Relative efficiency of using summary versus individual data in random-effects meta-analysis","volume":"76","author":"Chen","year":"2020","journal-title":"Biometrics"},{"key":"10.1016\/j.jtha.2025.09.009_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102358","article-title":"Fewer severe infections with tranexamic acid in patients with hematologic malignancies","volume":"8","author":"Poston","year":"2024","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:40:38Z","timestamp":1767602438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625005999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538783625005999"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}